retatrutide mechanism triple agonist gip glp-1 glucagon receptor ly3437943 Beyond GLP -1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based retatrutide mechanism triple agonist glp-1
Pay in 4 interest-free payments of $5.29 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10









/assets/production/practices/8374cadb2253e5496cfee3ef82ab5175a5e6343b/images/2820189.png)

















